3 Potential Catalysts That Could Lift Pfizer Stock Before 2025

With the total return of Pfizer's (NYSE: PFE) shares rising by just 1.9% this year so far, investors may be yearning for some kind of catalyst that will stimulate its stock price to rise at a better pace.They're in luck. Three such catalysts are coming in the next couple of months (likely before 2025 starts) that could precipitate some market movement for the stock. Let's take a look at each.As you've probably heard, the market for anti-obesity medicines is the hottest in biopharma right now. Pfizer's most advanced candidate, a molecule called danuglipron, has had a rough go at it, with middling efficacy and several worse-than-anticipated clinical trial readouts. Still, an earlier-stage program recently concluded its phase 1 trials, and it could easily constitute a catalyst for the stock price.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool